Lv0
0 积分 2025-08-01 加入
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
20天前
已完结
The Role of Energy Homeostasis in Depression Pathophysiology and Its Heterogeneity
20天前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
20天前
已完结
GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases
3个月前
已完结
Health policy and public health implications of obesity in China
3个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
3个月前
已完结
Obesity in China: current progress and future prospects
3个月前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
3个月前
已完结
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma
3个月前
已完结
SYHX1901, an oral dual JAK/SYK inhibitor, for moderate-to-severe plaque psoriasis: a randomized phase 2 trial
4个月前
已完结
皖公网安备34019202002308
